• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AbbVie (NY:ABBV)

    218.04 -10.16 (-4.45%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about AbbVie

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    88 89 Next >
    Why AbbVie Stock Flopped on Friday
    The market didn't exactly greet the company's latest earnings release with open arms. 
    Via The Motley Fool
    Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
    Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
    Via MarketMinute
    Topics Intellectual Property
    Exploring the top movers within the S&P500 index during today's session.
    Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
    Via Chartmill
    Looking Into AbbVie Inc's Recent Short Interest
     
    Via Benzinga
    AbbVie's Earnings Outlook
     
    Via Benzinga
    AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
    San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
    Via TokenRing AI
    Topics Artificial Intelligence Supply Chain
    Discover which S&P500 stocks are making waves on Friday.
    Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
    Via Chartmill
    AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
    The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
    Via TokenRing AI
    Topics Animal Testing Artificial Intelligence Economy
    Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
    Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive. 
    Via Benzinga
    Why AbbVie (ABBV) Shares Are Falling Today
    Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a... 
    Via StockStory
    Topics World Trade
    AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
    AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfolio growth. 
    Via Benzinga
    Gapping S&P500 stocks in Friday's session
    Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
    Via Chartmill
    AbbVie Q3 2025 Earnings Call Transcript
    AbbVie Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Economy
    ABBVIE INC (NYSE:ABBV) Reports Mixed Q3 2025 Results with EPS Beat and Revenue Miss
    AbbVie's Q3 2025 results show a mixed quarter with adjusted EPS beating estimates, but revenue missed and GAAP profit fell sharply. 
    Via Chartmill
    AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
    AbbVie stock dipped early Friday, though the drug giant easily beat views. 
    Via Investor's Business Daily
    AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates
    Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above... 
    Via StockStory
    Topics Earnings
    Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
    As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
    Via Benzinga
    Topics ETFs
    Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million
    Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million 
    Via The Motley Fool
    Topics Supply Chain
    AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect
    Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to know. 
    Via StockStory
    Topics Artificial Intelligence
    Want Decades of Passive Income? Buy This Index Fund and Hold It Forever.
    This ETF is one of the easiest ways to generate consistent passive income. 
    Via The Motley Fool
    Topics ETFs Regulatory Compliance Stocks
    Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?
    Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker. 
    Via The Motley Fool
    Topics Intellectual Property
    1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges
    When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
    Via StockStory
    Prediction: These Dividend Stocks Could Outperform Growth Stocks in the Next Decade
    Between growth and dividends, these companies have plenty to offer. 
    Via The Motley Fool
    Topics Economy Intellectual Property
    Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More
    Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 
    Via Benzinga
    ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop
    ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop 
    Via The Motley Fool
    Topics Energy Regulatory Compliance
    Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally
    Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally 
    Via The Motley Fool
    AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth
    AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth 
    Via The Motley Fool
    Topics Regulatory Compliance
    3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
    Via MarketBeat
    Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock
    Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock 
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing
    Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing 
    Via The Motley Fool
    Topics Regulatory Compliance
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    88 89 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.